CHICAGO (TheStreet) - -An experimental drug from Bristol-Myers Squibb that helps the immune system attack cancer cells was able to shrink tumors in patients with melanoma, kidney and non-small cell lung cancers, according to results from an early-stage study being presented later today at the American Society of Clinical Oncology (ASCO) annual meeting. The promising Bristol drug, BMS-936658, follows in the footsteps of Yervoy, another Bristol drug that was approved last year to treat melanoma and which also harnesses the power of a patient's immune system to fight cancer. Bristol is accelerating development of '658 and will push the drug into pivotal, phase III studies in lung cancer, melanoma and kidney cancer, based in part of the data presented at this year's ASCO meeting. ... Click to view a price quote on BMY. Click to research the Drugs industry.
Weiter zum vollständigen Artikel bei "TheStreet.com"